{"id":"W2154738014","doi":"10.1111/jth.13153","title":"Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial","year":2015,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Apixaban; Venous thromboembolism; Medicine; Cancer; Internal medicine; Intensive care medicine; Rivaroxaban; Atrial fibrillation; Thrombosis; Warfarin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007332649,0.0002201446,0.001153681,0.00009441715,0.0001225555,0.00005020967,0.0002035954,0.00009859523,0.00002870712],"category_scores_gemma":[0.0002385205,0.0001077629,0.0002762582,0.0001777487,0.0001427833,0.0001107928,0.00004334444,0.0001463713,0.000001179352],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002239337,"about_ca_system_score_gemma":0.000185398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005198214,"about_ca_topic_score_gemma":0.001040583,"domain_scores_codex":[0.9980249,0.00009972566,0.000932092,0.0002115253,0.0004650834,0.0002666826],"domain_scores_gemma":[0.9980474,0.0005781929,0.00053242,0.000335364,0.0003569403,0.000149709],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.09525979,0.04571104,0.03673706,0.0001876961,0.01236313,0.00003064297,0.0742979,0.001301679,0.0002265078,0.0008822927,0.2127718,0.5202304],"study_design_scores_gemma":[0.2110208,0.0246901,0.6197065,0.0005638638,0.00549329,0.000005577874,0.006603427,0.0002079027,0.001080495,0.001022176,0.1292556,0.000350222],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9838251,0.004025584,0.00002699108,0.009112396,0.001002408,0.001571685,0.0003433317,0.00000548159,0.00008704181],"genre_scores_gemma":[0.9801193,0.01793618,0.0004419806,0.0006968151,0.0006543498,0.00007870905,0.00002940617,0.00002709912,0.0000161027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5829694,"threshold_uncertainty_score":0.7858179,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1618100712664076,"score_gpt":0.3822552678402218,"score_spread":0.2204451965738141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}